Licensing Agreement (4907A)

TIDMONG

RNS Number : 4907A

Oxford Nutrascience Group PLC

02 February 2011

Oxford Nutrascience Group plc

("Oxford Nutrascience" or "the Company")

Exclusive License of Drug Delivery Technology from The University of Oxford

Oxford Nutrascience Group plc ("Oxford Nutrascience" or "the Company") announces that it has signed a worldwide exclusive licensing agreement with Isis Innovation Limited, the technology transfer company wholly-owned by the University of Oxford, to develop and commercialise products utilizing a novel drug delivery technology.

The drug delivery technology, which has been developed by Professor Dermot O'Hare and his research group at the University of Oxford's world renowned chemistry department, provides for outstanding taste masking, enhanced drug stability and potential for tuneable drug release properties.

Very significantly, the technology is applicable to a broad range of pharmaceuticals including major drug categories such as NSAIDS (Non-steroidal Anti-inflammatory drugs) and statins.

Recently Oxford Nutrascience has been developing taste masking for ibuprofen, a popular pain relief drug that is available over the counter (OTC), using ISIS Innovation's drug delivery technology.

The Company has recently established proof of concept for the taste masking of ibuprofen, which has removed the typical burning sensation on the throat. Following the signing of the licence with Isis Innovation Limited, Oxford Nutrascience is now proceeding to develop "no burn" chewable and liquid ibuprofen products which it intends to commercialise via the OTC and prescription markets.

ISIS Innovation's drug delivery technology is currently protected by a patent granted in the UK, Germany and France and an application has been made for the US. The Company is sponsoring research at The University of Oxford and is looking to file further patent applications during 2011.

Marcelo Bravo, Executive Chairman and Chief Technology Officer commented

"Licensing this technology from a strong academic partner such as the University of Oxford gives Oxford Nutrascience significant firepower to innovate and extend the lifecycle of existing branded generic medicines and soon to be off patent API's.

"The superior taste masking of ibuprofen and ease of formulation delivered by Isis Innovation's drug delivery technology will enable us to develop next generation ibuprofen products for markets worldwide."

- Ends -

For further information:

www.oxfordnutrascience.com

Oxford Nutrascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

Mark Way, Investor and Media Relations +44 7786 116991

ZAI Corporate Finance (Nominated Adviser)

Sarang Shah +44 20 7060 2220

John Depasquale +44 20 7060 2220

About Oxford Nutrascience Group Plc

-- Oxford Nutrascience is a speciality pharmaceutical company that uses novel pharmaceutics and drug delivery science to develop advanced medicines that extend the lifecycle of branded generics and soon to be off patent API's.

-- Oxford Nutrascience has developed technology for the use of prebiotic soluble fibres in medicine delivery systems that disperse and solubilise medicines, improve taste and mouth feel, simplify processing and eliminate additives.

-- Development work is currently focused on therapeutic categories including analgesics, bone health, indigestion and multivitamin and mineral supplements.

-- Oxford Nutrascience is establishing partnerships with a number of leading academic centers for pharmaceutics and has a growing number of technologies to apply to branded generics and API's.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRUGUQPPUPGGAG

Oxford Nutrascience (LSE:ONG)
過去株価チャート
から 11 2024 まで 12 2024